FDA warned China's Dermax Co., Ltd. over its website selling unapproved, misbranded injectable botulinum toxin to U.S. consumers.
What happened
FDA reviewed the company's website, www.dermaxshop.com, and found it offering injectable botulinum toxin drug products to U.S. consumers, including one marketed as "Botulax 100U." Website claims such as reducing sweating in underarms, palms, and feet showed the product is intended as a drug for human use. No FDA-approved application is in effect for that product, and its labeling does not give adequate directions for use, so FDA calls it an unapproved new drug (a drug sold without FDA approval) and misbranded (mislabeled under the law).
What FDA found
The company offers a botulinum toxin drug for sale in the U.S. with no FDA-approved application in effect for it.
Sections 301(d) and 505(a), FD&C Act [21 U.S.C. §§ 331(d), 355(a)]Website claims that the product reduces sweating in underarms, palms, and feet show it is intended to treat or affect the body, making it a drug.
Section 201(g) and 21 CFR 201.128The product's labeling does not give adequate directions for use, so a layperson could not use it safely.
Section 502(f)(1), FD&C Act [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5Because the drug is not approved in the U.S., it does not qualify for the exemption from the adequate-directions requirement.
21 CFR 201.115(a)By offering these prescription drugs for sale to U.S. consumers, the website causes misbranded drugs to enter interstate commerce.
Sections 301(a) and 503(b), FD&C Act [21 U.S.C. §§ 331(a), 353(b)]
What FDA wants
FDA tells the company to stop offering any unapproved and misbranded drugs for sale to U.S. consumers and to review its websites, labels, and promotional materials. It must reply in writing within 15 working days describing the steps taken and providing supporting documents.
Who should pay attention
- med spas, clinics, and estheticians who buy injectables online
- U.S. importers and distributors of aesthetic injectable drugs
- online platforms and payment processors that host foreign drug sellers
This is a summary. Read the original letter on fda.gov.